Carboxymethyllysine and carboxyethyllysine in multiple sclerosis patients

Area of Science:

• Biochemistry
• Neuroimmunology
• Pathophysiology

Background:

• Advanced glycation end-products (AGE) are implicated in the pathogenesis of various diseases.
• Neurodegenerative conditions like multiple sclerosis (MS) are associated with AGE accumulation.
• Protein glycation may play a role in the activity and progression of MS.

Purpose of the Study:

• To investigate the intensity of protein glycation in individuals with MS.
• To explore the association between glycation markers and MS disease activity.
• To compare glycation levels in MS patients versus healthy controls.

Main Methods:

• Serum samples were collected from 45 MS patients and 31 healthy controls.
• Concentrations of carboxymethyllysine (CML) and carboxyethyllysine (CEL) were quantified using ELISA.
• Statistical analyses were performed to compare groups and assess correlations.

Main Results:

• MS patients exhibited higher serum CML and CEL levels compared to healthy individuals, with a statistically significant increase in CML.
• A positive correlation between CML and CEL was observed only in the healthy control group.
• No significant differences in CML or CEL concentrations were found based on MS duration or Expanded Disability Status Scale (EDSS) scores.

Conclusions:

• Multiple sclerosis is characterized by heightened protein glycation, particularly CML formation.
• Disease duration and motor impairment (EDSS) do not appear to influence the progression of glycation in MS.
• The relationship between CML and CEL may be altered by the MS disease process.